D-0454-2023 Class III Terminated

Recalled by Akron Pharma, Inc. — Fairfield, NJ

FDA drug recall D-0454-2023 was initiated by Akron Pharma, Inc. on Feb 17, 2023 and is designated Class III. Reason for recall: Labeling: Incorrect or Missing Lot and/or Exp Date The recall status is terminated (terminated Sep 9, 2024). Affected quantity: 4,416 tubes.

Recall details

Product Type
Drugs
Report Date
Mar 15, 2023
Initiation Date
Feb 17, 2023
Termination Date
Sep 9, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,416 tubes

Product description

DIBUCAINE 1% HEMORRHOIDAL OINTMENT, 1 oz. (28 gm), Manufactured for: Akron Pharma Inc. Fairfield NJ 07004, NDC 71399-2829-1

Reason for recall

Labeling: Incorrect or Missing Lot and/or Exp Date

Distribution pattern

Nationwide within the United States

Code information

Lot #: 2206016, Exp. date 05/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0454-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0454-2023. Report a data issue: hello@regdatalab.com.